Oral corticosteroids did not reduce symptom severity or duration in patients with lower respiratory tract infections without asthma.
Researchers hypothosized that increased sputum Gammaproteobacteria:Firmicutes ratio may serve as a biomarker to guide antibiotic treatment in COPD.
Advanced emphysema may benefit from endoscopic lung reduction treatment.
People with COPD have been found to benefit from statin therapies, with reduced risk of all-cause and pulmonary-related mortality.
Patients with COPD treated with mucolytic agents for at least 1 year were better protected against exacerbations compared with patients treated with placebo.
Adults with asthma benefit from tailoring interventions based on sputum eosinophils vs clinical symptoms.
Researchers analyzed over 2.1 million patient-years' worth of data to determine the impact of short-acting beta agonist use in asthma.
Participants received 70 mg of tezepelumab every 4 weeks throughout the study.
FEV1 was higher in patients who received tiotropium therapy vs those in the placebo group.
International trends in asthma mortality are useful for assessing the effect of treatment strategies on the burden of asthma.
A 2015 update from the 1990 Global Burden of Disease study reveals current prevalence and mortality of asthma and chronic obstructive pulmonary disease.
A new algorithm developed by the National Institute for Health and Care Excellence was not useful for diagnosing asthma in children and adolescents.
The pathogeneses of steroid insensitivity in severe, steroid-resistant asthma may unlock new potential treatments.
Asthma is associated with development of inflammatory bowel disease.
Fluticasone furoate and vilanterol combination therapy reduced both daytime and nighttime symptoms in patients with persistent uncontrolled asthma.
Study results showed the benefit of single-inhaler triple therapy vs ICS/LABA therapy in COPD.
Recent research suggests that perioperative and postoperative pulmonary rehabilitation improves outcomes in patients undergoing thoracic surgery.
Inhaled corticosteroids for COPD does not increase the risk for fractures when used for short-term periods.
Elevated sputum eosinophil levels correlate with the severity of clinical outcomes in asthma.
A single-center study found that omalizumab led to reductions in allergic response much earlier than previously demonstrated.